Corporate Profile
Incorporated in 1974, Temasek Holdings is an Asia investment company headquartered in Singapore . Supported by 12 affiliates and offices in Asia and Latin America, Temasek owns a diversified S$172 billion (US$119 billion) portfolio as at 31 July 2009, concentrated principally in Singapore , Asia and the emerging economies.
Temasek’s investment themes centre on Transforming Economies, Growing Middle Income Populations, Deepening Comparative Advantages and Emerging Champions. Its portfolio covers a broad spectrum of industries: financial services; telecommunications & media; transportation & logistics; real estate; infrastructure, industrial & engineering; energy & resources; life sciences, consumer & lifestyle; and technology.
Total shareholder return for Temasek since its inception in 1974 has been a healthy 16 % compounded annually. It has a corporate credit rating of AAA/Aaa by rating agencies Standard & Poor’s and Moody’s respectively.
As a long-term investor, we have a stake in the lives and well-being of our fellow men. We recognise that social, environmental and governance factors can impact the larger community as well as the long-term sustainability of companies and businesses.
We actualise our commitment as a responsible corporate citizen by supporting efforts that build people and communities through education, healthcare and research; build bridges between peoples through deeper understanding and friendship; build better governance through a culture of integrity and excellence; and rebuild lives and livelihoods devastated by major natural disasters.
We have committed almost S$1 billion over the last decade to fund research institutions, scholarships and other public good beneficiaries, of which S$500 million was endowed to the Temasek Trust in May 2007. More recently, to mark our 35th anniversary, we gifted another S$100 million to the Temasek Trust, this time to support Temasek Cares for community programmes in Singapore.
| Company | Date | Round | Size | Participants |
| Marin Software | 2/12 | Series F | $30M | 6 |
| Portola Pharmaceuticals | 11/11 | Series D | $89M | 2 |
| Amyris Biotechnologies | 7/10 | Series D | $47.8M | 1 |
| SecondMarket | 2/10 | Series B | $15M | 2 |
| Harbour Networks Holdings | 3/05 | Series C | $37M | 4 |
